Companies: 10,795·Total market cap: $144.5T
Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc.

ESPRNASDAQHealthcare● Active
$3.14
+$0.01(+0.32%)
Market Cap$652833378
P/E Ratio
52W High$4.18
52W Low$0.95
SEC Filings

Esperion Therapeutics, Inc. (ESPR) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001434868 · ESPR · NASDAQ · as of Jun 8, 2026

Filing snapshot

893
Total Filings
DEFM14A
Latest Form
2026-06-08
Most Recent
2013
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001434868 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-10
Fiscal Year End
Mar 10, 2026
Accession No.
0001628280-26-016522
Primary Document
espr-20251231.htm
Source: data.sec.gov · CIK 0001434868 · Accession 0001628280-26-016522

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-08
8-KCurrent Report
8-K
2026-06-01Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
DEFM14ADEFM14A
DEFM14A
2026-06-08
View
8-KCurrent Report
8-K
2026-06-01
View
PREM14APREM14A
PREM14A
2026-05-29
View
10-QQuarterly Report
10-Q
2026-05-08
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-05-04
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-05-01
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-05-01
View
8-KCurrent Report
FORM 8-K
2026-05-01
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-04-22
View
ARSARS
ARS
2026-04-16
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-16
View
DEF 14AProxy Statement
DEF 14A
2026-04-16
View
8-KCurrent Report
8-K
2026-04-02
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-26
View
10-KAnnual Report
10-K
2026-03-10
View
Showing 1–15 of 505 filingsForm 4 / 144 hidden· 893 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001434868  |  Exchange: NASDAQ · Healthcare

Esperion Therapeutics, Inc. (NASDAQ: ESPR) has submitted 893 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2013. As a Healthcare sector company with CIK 0001434868, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Esperion Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Esperion Therapeutics, Inc. 10-K was filed on 2026-03-10 for fiscal year ending 2026. Historical ESPR 10-K annual reports are available from 2008 through 2026.

Investors researching Esperion Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

ESPR SEC Filings · 8 questions

Esperion Therapeutics, Inc. (ESPR) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 893 filings and access original documents at no cost. Esperion Therapeutics, Inc.'s CIK is 0001434868.

ESPR SEC filingsEsperion Therapeutics, Inc. SEC documentsfind ESPR 10-K